molecules of the month

A Ph. II liver-targeting HBV core protein modulator optimized for ADMET properties. Linvencorvir (RG7907), a novel HBV core protein allosteric modulator, offers a promising treatment option for chronic hepatitis B which affects 296 million people globally. It possesses an interesting glue-like mechanism that causes the HBV core protein to aggregate into incompetent capsids, reminiscent of HIV capsid modulator lenacapavir. Its potent anti-HBV activity, low CYP3A4 induction, favorable human PK, and promising safety have allowed it to reach Ph. II. The resolution of a CYP induction problem and a hERG issue aided by interesting co-crystal structures make this a valuable med chem case study, while the unmet need and mechanism of action make it a noteworthy pharmacological advance. The unmet medical…